Brief: SAGE Therapeutics Says To Reduce Workforce By About 33%
17/10/2024 12:27
Oct 17 (Reuters) - SAGE Therapeutics Inc SAGE.O :
* SAGE THERAPEUTICS ANNOUNCES STRATEGIC REORGANIZATION TO
PRIORITIZE ZURZUVAE® COMMERCIALIZATION AND FOCUS ITS DEVELOPMENT
PORTFOLIO
* SAGE THERAPEUTICS INC - TO REDUCE WORKFORCE BY
APPROXIMATELY 33%
* SAGE THERAPEUTICS INC - REORGANIZATION TO IMPACT OVER 165
EMPLOYEES
* SAGE THERAPEUTICS INC - EXPECTS NON-RECURRING CHARGE OF
$26M-$28M
* SAGE THERAPEUTICS INC - CHRIS BENECCHI TO BECOME CHIEF
OPERATING
OFFICER
Source text for Eikon: ID:nBw3zglT0a
Further company coverage: SAGE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sage Therapeutics
See all newsBrief: Supernus Pharmaceuticals Completes Acquisition Of Sage Therapeutics
Sage Therapeutics Inc Reports Results For The Quarter Ended June 30: Earnings Summary
SAGE Therapeutics Q2 revenue rises sequentially
Brief: Supernus Pharmaceuticals Announces Expiration Of Hart-Scott-Rodino Waiting Period For Sage Therapeutics Tender Offer
Sage Therapeutics Inc Expected To Post A Loss Of 95 Cents A Share: Earnings Preview